Blocking FGL1 in addition to anti-PD-L1 has the potential to become another novel ICB strategy in clinical practice, especially in the targeted therapy of non-small cell lung cancer (NSCLC).182. This evidence concerns the gene CD274 and non-small cell lung carcinoma.